In the first quarter, CSPC PHARMA's profit attributable to shareholders was approximately 1.478 billion yuan, a year-on-year decrease of 8.4%
CSPC PHARMA announced its Q1 2025 performance, with revenue of approximately RMB 7.015 billion, a year-on-year decrease of 21.9%; profit attributable to shareholders was approximately RMB 1.478 billion, a year-on-year decrease of 8.4%. Revenue from the pharmaceutical business was RMB 5.500 billion, down 27.3%, affected by industry policies. Revenue from raw material products increased by 14.6% to RMB 1.072 billion, with vitamin C sales revenue growing by 25.0%. R&D expenses increased by 11.4% to RMB 1.302 billion, accounting for approximately 23.7% of pharmaceutical business revenue
According to the Zhitong Finance APP, CSPC PHARMA (01093) announced its performance for the first quarter of 2025, with total revenue of approximately 7.015 billion yuan, a year-on-year decrease of 21.9%. The profit attributable to shareholders was approximately 1.478 billion yuan, a year-on-year decrease of 8.4%. Earnings per share were 12.91 cents.
Among them, the prescription drug business achieved revenue of 5.500 billion yuan during the period (including licensing fee income of 718 million yuan), a decrease of 27.3% compared to the same period last year, mainly due to the continued impact of industry policies such as centralized drug procurement and price adjustments of drugs in the national medical insurance drug catalog on the sales revenue of certain products.
The raw material product business saw sales revenue increase by 14.6% to 1.072 billion yuan compared to the same period last year. Driven by rising market demand and recovering product prices, the sales revenue of vitamin C products increased by 25.0% to 608 million yuan compared to the same period last year. The sales revenue of antibiotic products remained stable, slightly increasing by 3.3% to 464 million yuan compared to the same period last year.
Sales revenue from functional foods and other businesses decreased by 8.9% to 443 million yuan compared to the same period last year, mainly affected by the decline in market demand and product prices for caffeine.
Research and development expenses for the period increased by 11.4% to 1.302 billion yuan compared to the same period last year, accounting for approximately 23.7% of prescription drug business revenue. Currently, there are nearly 90 products in various stages of clinical trials, of which 10 have submitted applications for market approval, and over 30 key products are in the registration clinical stage